Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 4%

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) were up 4% during trading on Monday . The stock traded as high as $7.31 and last traded at $7.31. Approximately 469,948 shares were traded during trading, a decline of 73% from the average daily volume of 1,722,006 shares. The stock had previously closed at $7.03.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AUPH shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Down 0.8 %

The company has a market cap of $1.01 billion, a price-to-earnings ratio of -16.47 and a beta of 1.44. The firm’s 50 day simple moving average is $6.15 and its 200-day simple moving average is $5.58. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $57.10 million during the quarter, compared to analysts’ expectations of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) earnings per share. As a group, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current year.

Insider Activity

In related news, insider Scott Michael Habig sold 18,249 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the sale, the insider now owns 456,338 shares in the company, valued at $2,423,154.78. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AUPH. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $30,000. Tidemark LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $39,000. Banque Cantonale Vaudoise raised its stake in shares of Aurinia Pharmaceuticals by 126.6% in the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 5,410 shares during the period. Virtu Financial LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at $78,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $84,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.